Can a traditional Korean remedy help protect brain cells in Parkinson's

Current medications for Parkinson's, such as levodopa, are brilliant at topping up missing dopamine to manage daily movement challenges. However, they do not stop the condition from progressing or shield delicate brain cells from dying off over time. Searching for a way to actually protect the brain, researchers in South Korea recently tested a traditional East Asian remedy in the laboratory, with encouraging early results published in the journal Innovations in Acupuncture and Medicine in October 2026. What is inside this traditional medicine The researchers tested a liquid solution called BUM, which is commonly used in Korean clinics to calm severe inflammation, arthritis, back pain, and nerve pain. The scientific paper uses the Latin names for its three ingredients, Calculus Bovis, Fel Ursi, and Moschus, which are well known substances in traditional Asian medicine packed with active biological compounds. The first ingredient, Calculus Bovis (ox gallstones), contains natural bile acids that switch on the internal recycling systems of cells to clear out toxic protein waste while boosting growth signals that keep nerve cells alive. The second ingredient, Fel Ursi, is rich in ursodeoxycholic acid, often called UDCA. Many people in the Parkinson's community already know UDCA because it has been widely studied in modern clinical trials for its ability to repair and recharge the tiny energy factories inside our cells, known as mitochondria. The third ingredient, Moschus (musk), contains an active compound called muscone, which acts like a firefighter in the brain to cool down neuroinflammation and stop nerve cells from self destructing. Because Parkinson's is driven by several different problems happening at once, the scientists reasoned that combining these three ingredients could tackle toxic proteins, low cell energy, and brain inflammation simultaneously. A clever shortcut from the nose to the brain Getting medicine into the brain is notoriously difficult. When we swallow tablets, our digestive system and liver break down most of the active ingredients, and the brain's protective security fence, the blood brain barrier, blocks much of what is left. To bypass this obstacle, the researchers gave the BUM liquid to mice as simple nasal drops. Nerve pathways at the top of the nose lead straight into the brain, allowing the natural compounds to travel directly to the deep brain regions affected by Parkinson's without being destroyed by the stomach. Putting the remedy to the test The team tested this approach across two laboratory models: mice and microscopic roundworms. Mice given a chemical toxin that mimics Parkinson's quickly lost their balance, moved very slowly when climbing down a pole, and lost grip strength in their front paws. In contrast, mice given daily BUM nasal drops for ten days kept their balance, moved swiftly, and maintained strong grip strength, recovering their movement to a level very similar to mice treated with standard levodopa. Looking at the brain tissue under a microscope revealed why: the nasal drops had successfully protected the dopamine producing cells and their connecting nerve fibres from dying. Next, the scientists looked at microscopic roundworms engineered to produce human alpha synuclein, the sticky protein that forms harmful clumps in Parkinson's. When exposed to a chemical toxin, untreated worms suffered severe nerve damage and a massive buildup of these protein clumps. Pretreating the worms with the BUM solution shielded their dopamine nerves and reduced the sticky alpha synuclein clumps back down to nearly normal levels. What this means for people with Parkinson's Seeing a single formula improve movement, protect dopamine cells, and clear out sticky proteins in laboratory models highlights the exciting potential of combining multiple natural compounds and delivering them through gentle nasal drops. At the same time, it is important to stay grounded. This was a short, early stage study in mice and worms. The researchers still need to test whether the formula clears alpha synuclein in mammal brains, track exactly how the nasal drops travel through a larger brain, and standardise the exact chemical amounts in the mixture. While this remedy is not ready for human use today, it gives scientists a valuable new blueprint for designing multi targeted nasal therapies that might one day slow the progression of Parkinson's.